Spots Global Cancer Trial Database for recurrent renal cell carcinoma

Every month we try and update this database with for recurrent renal cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	NCT02867592	Adrenal Cortica... Alveolar Soft P... Central Nervous... Childhood Clear... Clear Cell Sarc... Ewing Sarcoma Hepatoblastoma Hepatocellular ... Osteosarcoma Recurrent Adren... Recurrent Alveo... Recurrent Clear... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Kidne... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Recurrent Renal... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Refractory Adre... Refractory Alve... Refractory Clea... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Oste... Refractory Prim... Refractory Prim... Refractory Rena... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory Wilm... Renal Cell Carc... Rhabdomyosarcom... Soft Tissue Sar... Solid Neoplasm Thyroid Gland M... Wilms Tumor	Cabozantinib Cabozantinib S-... Pharmacological...	2 Years - 30 Years	National Cancer Institute (NCI)
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery	NCT01061411	Clear Cell Sarc... Recurrent Renal... Stage III Renal... Stage IV Renal ...	Dalteparin Pharmacological... Sunitinib Malat...	18 Years -	Roswell Park Cancer Institute
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	NCT00126503	Chromophobe Ren... Clear Cell Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ...	Bevacizumab Sorafenib Tosyl... Pharmacological... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors	NCT02650635	Colorectal Aden... Metastatic Panc... Recurrent Breas... Recurrent Color... Recurrent Melan... Recurrent Non-S... Recurrent Pancr... Recurrent Renal... Solid Neoplasm Stage IV Breast... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr...	Cyclophosphamid... Laboratory Biom... Pegfilgrastim Pharmacological... TLR8 Agonist VT...	18 Years -	Mayo Clinic
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer	NCT01239342	Metastatic Kidn... Recurrent Renal... Stage III Renal... Stage IV Renal ...	Akt Inhibitor M... Everolimus Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	NCT04514484	Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi...	Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer	NCT00126594	Clear Cell Rena... Recurrent Renal... Stage IV Renal ...	Sorafenib Tosyl... Recombinant Int... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery	NCT01688973	Recurrent Renal... Stage III Renal... Stage IV Renal ... Type 1 Papillar... Type 2 Papillar...	Erlotinib Hydro... Laboratory Biom... Tivantinib	-	National Cancer Institute (NCI)
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer	NCT01767636	Carcinoma of th... Chromophobe Ren... Kidney Medullar... Kidney Oncocyto... Metastatic Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ...	Pazopanib Hydro...	18 Years -	Mayo Clinic
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer	NCT01727076	Head and Neck S... Recurrent Head ... Recurrent Non-S... Recurrent Renal... Recurrent Skin ... Stage III Renal... Stage IIIA Cuta... Stage IIIA Non-... Stage IIIB Cuta... Stage IIIB Non-... Stage IIIC Cuta... Stage IV Cutane... Stage IV Non-Sm... Stage IV Renal ...	Laboratory Biom... Pharmacological... Recombinant Hum...	19 Years -	National Cancer Institute (NCI)
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer	NCT02664883	Healthy Subject Metastatic Rena... Recurrent Renal... Stage I Renal C... Stage II Renal ... Stage III Renal...	Computed Tomogr... Cytology Specim... Laboratory Biom... Magnetic Resona...	25 Years -	University of Southern California
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors	NCT02650635	Colorectal Aden... Metastatic Panc... Recurrent Breas... Recurrent Color... Recurrent Melan... Recurrent Non-S... Recurrent Pancr... Recurrent Renal... Solid Neoplasm Stage IV Breast... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr...	Cyclophosphamid... Laboratory Biom... Pegfilgrastim Pharmacological... TLR8 Agonist VT...	18 Years -	Mayo Clinic
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer	NCT02298959	Clinical Stage ... Metastatic Colo... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Rena... Platinum-Resist... Recurrent Melan... Recurrent Renal... Refractory Mela... Refractory Rena... Sarcoma Stage IV Colore... Stage IV Ovaria... Stage IV Renal ...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Pembrolizumab Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer	NCT00126490	Recurrent Renal... Stage IV Renal ...	Aldesleukin Bevacizumab Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery	NCT00227760	Recurrent Renal... Stage IV Renal ...	Cediranib Malea... Dynamic Contras... Laboratory Biom... Pharmacological...	19 Years -	National Cancer Institute (NCI)
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer	NCT01239342	Metastatic Kidn... Recurrent Renal... Stage III Renal... Stage IV Renal ...	Akt Inhibitor M... Everolimus Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer	NCT03092856	Clear Cell Rena... Metastatic Rena... Recurrent Renal... Stage IV Renal ...	Anti-OX40 Antib... Axitinib Laboratory Biom... Placebo	18 Years -	University of Southern California
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy	NCT01198158	Clear Cell Rena... Recurrent Renal... Stage III Renal... Stage IV Renal ...	Bevacizumab Everolimus Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors	NCT01131234	Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Brain Ste... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Mixed Gli... Adult Solid Neo... Male Breast Car... Recurrent Adult... Recurrent Breas... Recurrent Colon... Recurrent Melan... Recurrent Non-S... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Recurrent Renal... Stage III Pancr... Stage III Renal... Stage IIIA Colo... Stage IIIA Non-... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Rect... Stage IIIA Skin... Stage IIIB Brea... Stage IIIB Colo... Stage IIIB Non-... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Rect... Stage IIIB Skin... Stage IIIC Brea... Stage IIIC Colo... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Rect... Stage IIIC Skin... Stage IV Breast... Stage IV Non-Sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Renal ... Stage IV Skin M... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta...	Gamma-Secretase... Cediranib Malea... Pharmacological... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	NCT00126503	Chromophobe Ren... Clear Cell Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ...	Bevacizumab Sorafenib Tosyl... Pharmacological... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer	NCT02298959	Clinical Stage ... Metastatic Colo... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Rena... Platinum-Resist... Recurrent Melan... Recurrent Renal... Refractory Mela... Refractory Rena... Sarcoma Stage IV Colore... Stage IV Ovaria... Stage IV Renal ...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Pembrolizumab Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)	NCT05935748	ccRCC Clear Cell Rena... Kidney Cancer Kidney Neoplasm... Renal Cancer Renal Neoplasms Recurrent Renal... Metastatic Rena... Refractory Rena... Advanced Renal ... Carcinoma Neoplasms Carcinoma, Rena... Neoplasms, Glan... Neoplasm by His... Adenocarcinoma Urologic Neopla... Urogenital Neop... Neoplasms by Si... Kidney Diseases Urologic Diseas...	NKT2152 palbociclib sasanlimab	18 Years -	NiKang Therapeutics, Inc.
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer	NCT01727089	Clear Cell Rena... Recurrent Renal... Stage IV Renal ... Type 1 Papillar... Type 2 Papillar...	Anti-Endoglin C... Bevacizumab Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma	NCT03229278	Lymphoma Metastatic Mali... Metastatic Mela... Metastatic Rena... Recurrent Bladd... Recurrent Class... Recurrent Head ... Recurrent Lymph... Recurrent Malig... Recurrent Renal... Stage III Bladd... Stage III Lymph... Stage III Non-S... Stage III Renal... Stage III Skin ... Stage IIIA Non-... Stage IIIA Skin... Stage IIIB Non-... Stage IIIB Skin... Stage IIIC Skin... Stage IV Bladde... Stage IV Lympho... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Bladd... Stage IVB Bladd... Unresectable He... Unresectable So...	Enzyme Inhibito... Laboratory Biom... Nivolumab Pembrolizumab	18 Years -	Rutgers, The State University of New Jersey
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma	NCT04300140	Clear Cell Rena...	Batiraxcept Cabozantinib (C... Nivolumab	18 Years -	Aravive, Inc.
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer	NCT00121251	Recurrent Renal... Stage III Renal... Stage IV Renal ...	Capecitabine Gemcitabine Hyd... Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer	NCT01767636	Carcinoma of th... Chromophobe Ren... Kidney Medullar... Kidney Oncocyto... Metastatic Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ...	Pazopanib Hydro...	18 Years -	Mayo Clinic
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma	NCT04300140	Clear Cell Rena...	Batiraxcept Cabozantinib (C... Nivolumab	18 Years -	Aravive, Inc.
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer	NCT01727089	Clear Cell Rena... Recurrent Renal... Stage IV Renal ... Type 1 Papillar... Type 2 Papillar...	Anti-Endoglin C... Bevacizumab Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma	NCT06049030	Renal Cell Carc...	HS-10516	18 Years - 75 Years	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer	NCT02664883	Healthy Subject Metastatic Rena... Recurrent Renal... Stage I Renal C... Stage II Renal ... Stage III Renal...	Computed Tomogr... Cytology Specim... Laboratory Biom... Magnetic Resona...	25 Years -	University of Southern California
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer	NCT00126490	Recurrent Renal... Stage IV Renal ...	Aldesleukin Bevacizumab Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations	NCT02646319	Advanced Malign... Cervical Squamo... Endometrial Car... Malignant Uteri... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Head ... Recurrent Malig... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Solid Neoplasm Stage III Bladd... Stage III Prost... Stage III Renal... Stage IIIA Brea... Stage IIIA Cerv... Stage IIIA Ovar... Stage IIIB Brea... Stage IIIB Cerv... Stage IIIB Ovar... Stage IIIC Brea... Stage IIIC Ovar... Stage IV Breast... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IVA Bladd... Stage IVA Cervi... Stage IVB Bladd... Stage IVB Cervi...	Laboratory Biom... Nanoparticle Al... Quality-of-Life...	18 Years -	Mayo Clinic
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer	NCT02318771	Head and Neck S... Metastatic Rena... Recurrent Head ... Recurrent Lung ... Recurrent Renal... Recurrent Skin ... Stage III Renal... Stage IV Lung C... Stage IV Skin M...	Radiation Thera... MK-3475	18 Years -	Thomas Jefferson University
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation	NCT05641935	Recurrent Renal... Renal Cell Carc...	Sulfur Hexafluo... Contrast-Enhanc... Computed Tomogr... Magnetic Resona... Electronic Heal...	18 Years -	Thomas Jefferson University
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy	NCT01198158	Clear Cell Rena... Recurrent Renal... Stage III Renal... Stage IV Renal ...	Bevacizumab Everolimus Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer	NCT00083109	Recurrent Renal... Stage IV Renal ...	Fluorouracil Pharmacological... Suramin	18 Years -	National Cancer Institute (NCI)
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer	NCT02298959	Clinical Stage ... Metastatic Colo... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Rena... Platinum-Resist... Recurrent Melan... Recurrent Renal... Refractory Mela... Refractory Rena... Sarcoma Stage IV Colore... Stage IV Ovaria... Stage IV Renal ...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Pembrolizumab Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: